Comparative Pharmacology
Head-to-head clinical analysis: POSACONAZOLE versus VORICONAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POSACONAZOLE versus VORICONAZOLE.
POSACONAZOLE vs VORICONAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Posaconazole inhibits fungal CYP450-dependent 14α-demethylase, blocking ergosterol synthesis, disrupting fungal cell membrane integrity and function.
Inhibits fungal CYP450-dependent 14α-lanosterol demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
300 mg orally twice daily on day 1, then 300 mg once daily thereafter. Extended-release tablets: 300 mg orally twice daily on day 1, then 300 mg once daily. Intravenous: 300 mg IV twice daily on day 1, then 300 mg once daily.
Loading dose: 6 mg/kg IV every 12 hours for 2 doses, then maintenance 4 mg/kg IV every 12 hours; or 200–300 mg PO every 12 hours (400 mg PO every 12 hours for first 24 hours as loading dose if no IV).
MODERATE Risk
MODERATE Risk
Clinical Note
moderateVoriconazole + Tranilast
"The risk or severity of adverse effects can be increased when Voriconazole is combined with Tranilast."
Clinical Note
moderatePosaconazole + Tranilast
"The risk or severity of adverse effects can be increased when Posaconazole is combined with Tranilast."
Clinical Note
moderateVoriconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Voriconazole is combined with Tolfenamic acid."
Clinical Note
moderateTerminal elimination half-life: 35 hours (range 25–50 hours), allowing once-daily dosing after steady state; prolonged in hepatic impairment.
The terminal elimination half-life is approximately 6 hours for CYP2C19 extensive metabolizers. In poor metabolizers (which occur in 15-20% of Asian populations), the half-life can be prolonged to up to 24 hours. Clinical context: Dosing adjustments may be necessary based on CYP2C19 genotype; the short half-life necessitates twice-daily dosing for most patients.
Fecal (77% as unchanged drug) and renal (14% as glucuronide conjugates); <1% excreted unchanged in urine.
Voriconazole is primarily metabolized in the liver via CYP2C19, CYP3A4, and to a lesser extent CYP2C9. Less than 2% of the dose is excreted unchanged in urine. Fecal excretion accounts for approximately 20% of the dose, with the remainder as metabolites in urine. Overall, renal elimination of unchanged drug is negligible, but metabolites are excreted renally.
Category C
Category D/X
Azole Antifungal
Azole Antifungal
Posaconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Posaconazole is combined with Tolfenamic acid."